Filip Baert - Concepedia

Author

Filip Baert

Also Known As

BAERT F, Baert, Filip, Danny De Looze, F Baert, F. Baert, Filip Baert, Flo Baert, Jean-Francois Rahier, Mojgan, Pál Miheller

251

Publications

18.9K

Citations

H-Index

Concepts

All Affiliations

KU Leuven AZ Delta Imelda Hospital Centre Hospitalier Universitaire de Liège Ghent University Hospital

About

Filip Baert is an author at KU Leuven specializing in medicine, gastroenterology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	47	10.9K
2	Allergy	3	3	163
3	Health Sciences	2	2	102
4	Engineering	1	1	10
5	Public Health	1	2	74

Filip Baert

Publications

17.7K

Citations

H-Index

Page 1

	Year	Citations
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease Filip Baert, Maja Noman, Séverine Vermeire, New England Journal of Medicine	2003	2K
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD Marco Daperno, Geert D’Haens, Gert Van Assche, Gastrointestinal Endoscopy Endoscopic ImagingInterventional Endoscopic UltrasoundGastroenterologyGi TechniqueSurgery	2004	1.7K
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Geert D’Haens, Filip Baert, Gert Van Assche, The Lancet Autoimmune DiseaseImmunosuppressive TherapyImmunologyGastroenterologyClinical Gastroenterology	2008	1.2K
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt, The Lancet GastroenterologyTight Control ManagementClinical GastroenterologyUlcerative ColitisMedicine	2017	883
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum Geert D’Haens, Karel Geboes, Filip Baert, Gastroenterology Excluded IleumGastroenterologyPathologyGastrointestinal PathologyDigestive Tract	1998	862
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease Filip Baert, Liesbeth Moortgat, Gert Van Assche, Gastroenterology InflammationMucosal ImmunologyImmunologyGastroenterologyClinical Gastroenterology	2009	821
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease Geert D’Haens, Marc Ferrante, Séverine Vermeire, Inflammatory Bowel Diseases	2012	797
Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial Geert D’Haens, Sander van Deventer, Ruud van Hogezand, Gastroenterology InflammationAnti-inflammatoryAutoimmune DiseaseImmunologyGastroenterology	1999	753
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease Séverine Vermeire, M. Noman, Gert Van Assche, Gut	2007	599
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Gastroenterology InflammationDisease TreatedAutoimmune DiseaseImmunosuppressive TherapyImmunology	2008	494

Page 1